Login to Your Account

Neuroderm sees positive phase II data pump up shares

By Michael Fitzhugh
Staff Writer

Wednesday, March 1, 2017

Neuroderm Ltd. shares climbed 26.6 percent Wednesday to $29.30 on word that a 24-hour regimen of its continuous delivery LD/CD candidate, ND0612H, significantly decreased the amount of time in which PD patients faced a reemergence of PD symptoms on medication.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription